In the third session from the Platelet Reactivity Testing Round Table, the panel discuss treatment options for high-risk PCI patients.
Among the many fascinating points discussed in this session are a number of key issues including:
||A review of types of procedures in peripheral intervention that require antiplatelet therapy
||What does the antiplatelet therapy consist of in peripheral interventional cases?
||Are we rational in how we are approaching the choice in terms of mono-therapy in PAD patients?
||What is the evidence in PAD intervention in terms of the impact of clopidegrel response on the risk on negative outcomes?
||Is there a relationship between size of the artery and thrombotic risk?
||In terms of drug response, are there clear lessons from peripheral arterial intervention that can be taken from cardiology?
||How common are major bleeding complications in peripheral arterial interventions?
||Are we going to see more studies in different organ areas as we have seen in cardiology?
Robert Storey, Professor and Honorary Consultant in Cardiology, Department of Cardiovascular Science, University of Sheffield, UK (Chair)
Stavros Spiliopoulos, Patras University Hospital, Rion, Greece
Jeff Daheln, Chief Scientific Officer, Accumetrics, US
Designed to support the continuous education of practicing physicians, this roundtable shares leading opinion and addresses the following questions and key educational objectives:
- Increase physician awareness of the multidisciplinary role of antiplatelet therapy
- Increase understanding of the role of platelet function testing in high-risk PCI
- Explain the emerging role of PFT in PAD
- Assess the role of antiplatelets in neuro-endovascular procedures
This round table discussion is intended for an international audience, specifically interventional cardiologists, interventional radiologists and aligned healthcare professional involved with antiplatelet therapy.
The Round Table Event was supported by Accumetrics.